Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 2600 of 3499 entries
View as:

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00012298 Org: User:
Start: 04/30/01 End: 04/30/10 Due: 04/30/11

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

Phase: N/A Priority: Normal
NCT ID: NCT05237934 Org: User:
Start: 04/25/22 End: 12/31/32 Due: 12/31/33

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00004862 Org: User:
Start: 10/31/99 End: - Due: -

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00039403 Org: User:
Start: 04/30/02 End: - Due: -

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

Phase: N/A Priority: Normal
NCT ID: NCT00357708 Org: User:
Start: 06/30/06 End: - Due: -

Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00007917 Org: User:
Start: 01/31/01 End: 10/31/10 Due: 10/31/11

A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT00045396 Org: User:
Start: 06/30/02 End: - Due: -

Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing

Phase: N/A Priority: Normal
NCT ID: NCT01031641 Org: User:
Start: 11/19/09 End: 07/16/20 Due: 07/16/21

Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy People for the Expansion of T Cells for Adoptive Cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02821806 Org: User:
Start: 08/08/16 End: 02/01/35 Due: 02/01/36

Radium-223 in Biochemically Recurrent Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04206319 Org: User:
Start: 09/22/20 End: 11/15/27 Due: 11/15/28

PXD101 in Treating Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00357032 Org: User:
Start: 05/31/06 End: 07/31/10 Due: 07/31/11

PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00354185 Org: User:
Start: 05/31/06 End: - Due: -

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03816358 Org: User:
Start: 12/09/19 End: 01/31/26 Due: 01/31/27

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01711515 Org: User:
Start: 10/01/12 End: 07/17/20 Due: 07/17/21

Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

Phase: N/A Priority: Normal
NCT ID: NCT00055237 Org: User:
Start: 02/26/03 End: 03/15/10 Due: 03/15/11

Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00330161 Org: User:
Start: 03/31/06 End: 05/31/11 Due: 05/31/12

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01255137 Org: User:
Start: 09/30/10 End: 12/31/12 Due: 12/31/13

A Pilot Study of Topical Antiflammin-2 for Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00001371 Org: User:
Start: 12/31/93 End: 12/31/00 Due: 12/31/01

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03759184 Org: User:
Start: 07/11/19 End: 10/22/21 Due: 10/22/22

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04074135 Org: User:
Start: 06/02/20 End: 07/01/36 Due: 07/01/37

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02415153 Org: User:
Start: 07/14/15 End: 05/27/20 Due: 05/27/21

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

Phase: N/A Priority: Normal
NCT ID: NCT02417753 Org: User:
Start: 04/03/15 End: 04/07/16 Due: 04/07/17

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01441128 Org: User:
Start: 09/01/11 End: 02/26/15 Due: 02/26/16

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01802320 Org: User:
Start: 03/31/13 End: 08/05/15 Due: 08/05/16

Gene Therapy for Patients With Leukocyte Adherence Deficiency (Follow-Up of Phase 1 Trial)

Phase: N/A Priority: Normal
NCT ID: NCT00023010 Org: User:
Start: 08/15/01 End: 12/13/10 Due: 12/13/11